Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Y Chiang

Showing results (21-30 of 24) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 24 results.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|December 5, 2006
Evaluation of interleukin-6, interleukin-10 and human hepatocyte growth factor as tumor markers for hepatocellular carcinomaC-Y Hsia, T-I Huo, S-Y Chiang, et al.
Oncogene|November 11, 2014
Angiomotin decreases lung cancer progression by sequestering oncogenic YAP/TAZ and decreasing Cyr61 expressionY-L Hsu, J-Y Hung, S-H Chou, et al.
British Journal of Pharmacology|May 9, 2009
Comprehensive evaluation of a novel nuclear factor-kappaB inhibitor, quinoclamine, by transcriptomic analysisW-Y Cheng, J-C Lien, C-Y Hsiang, et al.
Neuroepidemiology|August 7, 2003
Epidemiological and genetic studies of myotonic dystrophy type 1 in TaiwanK M Hsiao, S S Chen, S Y Li, et al.
Pageof 3

Showing results (21-30 of 24) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 24 results.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|December 5, 2006
Evaluation of interleukin-6, interleukin-10 and human hepatocyte growth factor as tumor markers for hepatocellular carcinomaC-Y Hsia, T-I Huo, S-Y Chiang, et al.
Oncogene|November 11, 2014
Angiomotin decreases lung cancer progression by sequestering oncogenic YAP/TAZ and decreasing Cyr61 expressionY-L Hsu, J-Y Hung, S-H Chou, et al.
British Journal of Pharmacology|May 9, 2009
Comprehensive evaluation of a novel nuclear factor-kappaB inhibitor, quinoclamine, by transcriptomic analysisW-Y Cheng, J-C Lien, C-Y Hsiang, et al.
Neuroepidemiology|August 7, 2003
Epidemiological and genetic studies of myotonic dystrophy type 1 in TaiwanK M Hsiao, S S Chen, S Y Li, et al.
Pageof 3